JP2018526424A5 - - Google Patents

Download PDF

Info

Publication number
JP2018526424A5
JP2018526424A5 JP2018513363A JP2018513363A JP2018526424A5 JP 2018526424 A5 JP2018526424 A5 JP 2018526424A5 JP 2018513363 A JP2018513363 A JP 2018513363A JP 2018513363 A JP2018513363 A JP 2018513363A JP 2018526424 A5 JP2018526424 A5 JP 2018526424A5
Authority
JP
Japan
Prior art keywords
optionally substituted
disease
bromodomain
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018513363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526424A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/051017 external-priority patent/WO2017044792A1/en
Publication of JP2018526424A publication Critical patent/JP2018526424A/ja
Publication of JP2018526424A5 publication Critical patent/JP2018526424A5/ja
Pending legal-status Critical Current

Links

JP2018513363A 2015-09-11 2016-09-09 アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用 Pending JP2018526424A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217544P 2015-09-11 2015-09-11
US62/217,544 2015-09-11
PCT/US2016/051017 WO2017044792A1 (en) 2015-09-11 2016-09-09 Acetamide thienotriazoldiazepines and uses thereof

Publications (2)

Publication Number Publication Date
JP2018526424A JP2018526424A (ja) 2018-09-13
JP2018526424A5 true JP2018526424A5 (enExample) 2019-10-17

Family

ID=58240133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513363A Pending JP2018526424A (ja) 2015-09-11 2016-09-09 アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用

Country Status (21)

Country Link
US (2) US10881668B2 (enExample)
EP (1) EP3347020A4 (enExample)
JP (1) JP2018526424A (enExample)
KR (1) KR20180051576A (enExample)
CN (1) CN108472299A (enExample)
AU (2) AU2016319785C1 (enExample)
BR (1) BR112018004617A2 (enExample)
CA (1) CA2996977A1 (enExample)
CL (1) CL2018000622A1 (enExample)
CO (1) CO2018002568A2 (enExample)
CR (1) CR20180199A (enExample)
HK (1) HK1256419A1 (enExample)
IL (1) IL257593A (enExample)
MX (1) MX2018003030A (enExample)
PE (1) PE20181086A1 (enExample)
PH (1) PH12018550026A1 (enExample)
RU (1) RU2018112953A (enExample)
SG (1) SG10202007099TA (enExample)
UA (1) UA123946C2 (enExample)
WO (1) WO2017044792A1 (enExample)
ZA (1) ZA201801549B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体の使用
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体およびその使用
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
HK1256419A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
CN107629057B (zh) * 2016-07-19 2020-03-27 上海勋和医药科技有限公司 Bet蛋白抑制剂及其应用
AU2018334788B2 (en) * 2017-09-22 2022-11-24 CSPC Zhongqi Pharmaceutical Technology(Shijiazhuang) Co., Ltd. Thienodiazepine derivatives and application thereof
US20220177490A1 (en) * 2019-03-07 2022-06-09 Medshine Discovery Inc. Compounds having both effects of bet bromodomain protein inhibition and pd-l1 gene regulation
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
CN112444582B (zh) * 2021-02-01 2021-06-04 宁波大学 基于液滴萃取的质谱分析方法
CN113816970B (zh) * 2021-09-18 2022-08-09 济宁医学院附属医院 一种选择性铜离子螯合剂、其制备方法及其在肺纤维化中的应用

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3709898A (en) 1971-02-09 1973-01-09 Upjohn Co Process for the production of triazolobenzodiazepines and intermediates
US3681343A (en) 1971-05-11 1972-08-01 Upjohn Co 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines
US3812259A (en) 1971-08-09 1974-05-21 Upjohn Co Animal feed and process
CH622019A5 (en) 1975-10-23 1981-03-13 Upjohn Co Process for the preparation of aminotriazolobenzodiazepines
FR2329668A1 (fr) 1975-10-27 1977-05-27 Upjohn Co Procede de preparation d'aminotriazolobenzodiazepines
EP0087850A1 (en) 1982-01-04 1983-09-07 The Upjohn Company Benzodiazepines for anti-hypertensive use
DE3435973A1 (de) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
ZA87377B (en) 1986-01-21 1988-09-28 Boehringer Ingelheim Int New thieno-1,4-diazepine
DE3724164A1 (de) 1986-07-25 1988-01-28 Boehringer Ingelheim Kg Neue 1,4-benzodiazepine, ihre herstellung und verwendung
US4960770A (en) 1987-05-28 1990-10-02 Yoshitomi Pharmaceutical Industries, Ltd. 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses thereof
JPH0676326B2 (ja) 1988-05-24 1994-09-28 吉富製薬株式会社 循環器系疾患治療薬
EP0368175A1 (de) * 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0387613A1 (de) 1989-03-03 1990-09-19 Boehringer Ingelheim Kg Neue Thienodiazepine
CA2020806A1 (en) 1989-07-12 1991-01-13 Karl-Heinz Weber Thienodiazepine derivatives
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
JP2959591B2 (ja) 1990-05-23 1999-10-06 吉富製薬株式会社 チエノトリアゾロジアゼピン化合物
DE4107521A1 (de) 1991-03-08 1992-09-10 Boehringer Ingelheim Kg Neue acylaminosubstituierte hetrazepine
KR100255493B1 (ko) 1991-10-11 2000-08-01 가마쿠라 아키오 골조송증 치료제
EP0661284A1 (en) * 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
EP0692483A1 (en) 1993-03-30 1996-01-17 Yoshitomi Pharmaceutical Industries, Ltd. Cell adhesion inhibitor and thienotriazolodiazepine compound
JP3001979U (ja) 1994-03-14 1994-09-06 有限会社マルセ木工 竿掛け具
WO1995032963A1 (en) * 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
WO1996020941A1 (de) 1995-01-06 1996-07-11 F. Hoffmann-La Roche Ag Hydroxymethyl-imidazodiazepine und deren ester
BR9610390A (pt) 1995-09-09 1999-07-06 Hoffmann La Roche O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
CA2258053A1 (en) 1996-06-12 1997-12-18 Yoshihisa Yamamoto Cytokine production inhibitors, triazepine compounds, and intermediates thereof
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
DE69717160T2 (de) 1996-09-13 2003-05-08 Mitsubishi Pharma Corp., Osaka Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
US6444664B1 (en) 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
JPH11228576A (ja) 1997-12-10 1999-08-24 Japan Tobacco Inc アポトーシス抑制剤
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US7589167B2 (en) 2000-02-22 2009-09-15 J. David Gladstone Institutes ZA loops of bromodomains
WO2001095912A1 (fr) 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
WO2002002557A2 (en) 2000-06-30 2002-01-10 Neurogen Corporation 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
US20060142257A1 (en) 2001-01-19 2006-06-29 Eberhard Nieschlag Male contraceptive formulation comprising norethisterone
US6979682B2 (en) 2001-02-23 2005-12-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
NZ531928A (en) 2001-09-04 2005-10-28 Boehringer Ingelheim Pharma Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
US20030216758A1 (en) 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
JP3096299U (ja) 2003-02-20 2003-09-12 宇輪工業股▲ふん▼有限公司 足踏み式健康器
MXPA05009068A (es) 2003-02-26 2005-10-19 Boehringer Ingelheim Pharma Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos.
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
WO2005002526A2 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
CA2538413A1 (en) 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
JP2008510771A (ja) 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
GB0419161D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
JP5159305B2 (ja) 2005-05-30 2013-03-06 田辺三菱製薬株式会社 チエノトリアゾロジアゼピン化合物及びその医薬としての用途
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
EP1915155A1 (en) 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
DK1951684T3 (en) 2005-11-01 2016-10-24 Targegen Inc BIARYLMETAPYRIMIDIN kinase inhibitors
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
KR20080083680A (ko) 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제
KR101062583B1 (ko) 2006-01-17 2011-09-06 에프. 호프만-라 로슈 아게 Gaba 수용체에 의해 알츠하이머병의 치료에 유용한아릴-아이속사졸-4-일-이미다조[1,2-a]피리딘
KR20080095902A (ko) 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
ES2351367T3 (es) 2006-02-14 2011-02-03 Vertex Pharmaceuticals Incorporated Dihidrodiazepinas útiles como inhibidores de proteína quinasas.
US20070218135A1 (en) 2006-03-14 2007-09-20 Glenmark Pharmaceuticals Limited Sustained release matrix pharmaceutical composition
DE602007008553D1 (de) 2006-05-03 2010-09-30 Novartis Ag Verwendung von organischen verbindungen
WO2007135374A1 (en) 2006-05-19 2007-11-29 Astrazeneca Ab Dihydropteridine compounds as anti proliferative agents
WO2008009909A1 (en) 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
MX2009004077A (es) 2006-10-19 2009-05-05 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Brd2ブロモドメイン結合剤
PT2114873E (pt) 2006-12-26 2013-05-06 Lantheus Medical Imaging Inc Ligandos para imagiologia de inervação cardíaca
PT2139892E (pt) 2007-03-22 2011-11-21 Takeda Pharmaceutical Pirimidodiazepinas substituídas úteis como inibidores da plk1
WO2008137081A1 (en) 2007-05-02 2008-11-13 The Trustees Of Columbia University In The City Of New York Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives
KR20080107050A (ko) 2007-06-05 2008-12-10 울산대학교 산학협력단 항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
EP2190849B1 (en) 2007-08-15 2013-11-20 Vertex Pharmceuticals Incorporated 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
NZ584760A (en) 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
EP2610256B1 (en) 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2009080638A2 (en) 2007-12-20 2009-07-02 Cellzome Limited Sulfamides as zap-70 inhibitors
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
JP5480824B2 (ja) 2008-03-10 2014-04-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Plkキナーゼ阻害剤としての4−アリール−2−アニリノ−ピリミジン
EP2276747A1 (en) 2008-03-11 2011-01-26 Cellzome Limited Sulfonamides as zap-70 inhibitors
FR2928923B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
WO2010015340A1 (en) 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
WO2010032195A1 (en) 2008-09-16 2010-03-25 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
AU2009309691B2 (en) 2008-10-30 2015-04-02 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
CN102341394B (zh) 2009-01-23 2015-04-15 武田药品工业株式会社 聚(adp-核糖)聚合酶(parp)抑制剂
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
AU2010299579A1 (en) 2009-09-25 2012-05-03 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919433D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US9102677B2 (en) * 2009-11-05 2015-08-11 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2652304T3 (es) 2009-11-05 2018-02-01 Glaxosmithkline Llc Compuesto de benzodiacepina novedoso
WO2011101369A1 (en) 2010-02-17 2011-08-25 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
EP2902030B1 (en) * 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
US20130252331A1 (en) * 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism
WO2011143660A2 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
CN103180318B (zh) * 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
US20120014979A1 (en) 2010-07-16 2012-01-19 Alexander Dent Use of bcl6 inhibitors for treating autoimmune diseases
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9249161B2 (en) * 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
AU2012220620A1 (en) 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CA2826674A1 (en) 2011-03-07 2012-09-13 Fondazione Telethon Tfeb phosphorylation inhibitors and uses thereof
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
AU2013221230A1 (en) 2012-02-17 2014-10-02 Ansun Biopharma, Inc. Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
US20150133434A1 (en) 2012-03-28 2015-05-14 The J. David Gladstone Institutes Compositions and Methods for Reactivating Latent Immunodeficiency Virus
CA2878996C (en) 2012-08-08 2021-09-14 Novomatic Ag Method of and system for tracking gaming activity
US9663523B2 (en) * 2012-09-28 2017-05-30 Bayer Pharma Aktiengesellschaft BET protein-inhibiting 5-aryltriazoleazepines
EP2900221B1 (en) 2012-09-28 2019-03-06 Oncoethix GmbH Pharmaceutical formulation containing thienotriazolodiazepine compounds
EP2917203B1 (en) 2012-11-02 2019-04-03 Dana-Farber Cancer Institute, Inc. Method for identifying myc inhibitors
HK1213899A1 (zh) 2012-12-20 2016-07-15 Bayer Pharma Aktiengesellschaft 抑制bet蛋白的二氢吡啶并吡嗪酮
US20140254659A1 (en) 2013-03-11 2014-09-11 Mediatek Inc. Video coding method using at least evaluated visual quality and related video coding apparatus
EP2970285B1 (en) 2013-03-11 2019-04-17 AbbVie Inc. Fused tetracyclic bromodomain inhibitors
CN105026403B (zh) 2013-03-12 2018-05-18 艾伯维公司 四环布罗莫结构域抑制剂
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
US10739333B2 (en) 2013-09-19 2020-08-11 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
WO2015081280A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
WO2015081284A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
US9994581B2 (en) 2013-12-10 2018-06-12 Abbvie Inc. Bromodomain inhibitors
US20160347750A1 (en) 2014-01-31 2016-12-01 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体の使用
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
JP2017504650A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体およびその使用
WO2015129927A1 (en) * 2014-02-26 2015-09-03 Kyorin Pharmaceutical Co., Ltd. Heterocyclic compounds
CN106456653A (zh) * 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体およびその使用
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
CN107223057A (zh) * 2014-12-05 2017-09-29 H·李·莫菲特癌症中心研究所公司 布罗莫结构域抑制剂作为癌症免疫治疗的补充剂
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP7269731B2 (ja) 2015-03-18 2023-05-09 アルビナス・オペレーションズ・インコーポレイテッド 標的タンパク質の分解向上のための化合物および方法
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3331905B1 (en) * 2015-08-06 2022-10-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US10772962B2 (en) * 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
PT3347356T (pt) * 2015-09-09 2021-06-28 Jubilant Biosys Ltd Derivados tricíclicos de piridinaa-2-ona fundidos e a sua utilização como inibidores brd4
PE20181287A1 (es) * 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
HK1256419A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
EP3347353B1 (en) 2015-09-11 2019-07-17 Boehringer Ingelheim International GmbH Pyrazolyl-substituted heteroaryls and their use as medicaments
SG10201913450PA (en) * 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
ES2970864T3 (es) 2015-11-25 2024-05-31 Visterra Inc Moléculas de anticuerpos contra APRIL y usos de las mismas
ES2943235T3 (es) 2015-11-25 2023-06-12 Gilead Apollo Llc Composiciones fungicidas que contienen derivados de 2,4-dioxo-1,4-dihidrotieno[2,3-d]pirimidina
MX2018006287A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc de triazol y usos de los mismos.
KR20180082558A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 에스테르 acc 억제제 및 그의 용도
AU2016361412A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
ES2974439T3 (es) 2015-11-25 2024-06-27 Effector Therapeutics Inc Compuestos inhibidores de EIF4-A y métodos relacionados con los mismos
CN108290858B (zh) 2015-12-01 2021-07-06 日本农药株式会社 3h-吡咯并吡啶化合物或其n-氧化物、或它们的盐类及含有该化合物的农业园艺用杀虫剂及其使用方法
WO2017197046A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109790143A (zh) * 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017201069A1 (en) * 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
GB201608797D0 (en) 2016-05-19 2016-07-06 Ucb Biopharma Sprl Therapeutic use
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase

Similar Documents

Publication Publication Date Title
JP2018526424A5 (enExample)
JP2017504650A5 (enExample)
JP2020055813A5 (enExample)
JP2018526421A5 (enExample)
RU2018112953A (ru) Ацетамидтиенотриазолодиазепины и пути их применения
RU2018112961A (ru) Цианотиенотриазолодиазепины и пути их применения
JP2017504651A5 (enExample)
RU2016134941A (ru) Производные диазепана и их применения
RU2018122641A (ru) Бивалентные ингибиторы бромодоменов и пути их применения
TWI770552B (zh) 喹唑啉化合物
ES2648876T3 (es) Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo
RU2017104897A (ru) Производные диазепана и их применения
RU2017104898A (ru) Дигидроптеридиноновые производные и их применения
JP6474068B2 (ja) 2−アミノピリミジン系化合物およびその薬物組成物と使用
JP2018538281A5 (enExample)
JP2016531113A5 (enExample)
KR20180132861A (ko) Bet 단백질 분해제
Wang et al. Design, synthesis and biological activity of N-(2-phenoxy) ethyl imidazo [1, 2-a] pyridine-3-carboxamides as new antitubercular agents
WO2013033270A2 (en) Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
MXPA05002572A (es) Compuestos pirazolo[1,5-a]pirimidinas como inhibidores de cinasa depentes de ciclina.
RU2016133196A (ru) Дигидроптеридиноновые производные и их применения
JP2006512339A5 (enExample)
JP2016505010A5 (enExample)
JP2025102917A (ja) 療法に使用するためのparp14の標的タンパク質分解
ES2338060T3 (es) Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer.